深度揭秘Rich

穷人不懂什么叫“资本”（文章来源：凤凰网论坛）投资致富的先决条件是将资产投资于高报酬率的投资标的上。

而存放在银行无异于虚耗光阴，浪费资源。

穷人之所以穷，很多时候不是因为没有梦想，而是没有去把梦想变成现实。

有1万元钱，5个人分，每人可得2000元，谁也不穷，谁也不富。

要是其中的两个人用自己的2000元去做生意，每人又赚了1万元，那么这个社会的财富总量就达到了3万元。

而其中的两个富人拥有2.4万元，占80％，三个穷人拥有6000元，占20％。

在这种情况下，我们能说三个穷人“穷了”是因为两个富人“富了”吗？不能。

因为两个富人的“富”来自于社会财富的“增量”，而不是从另三个人手中夺取的“存量”。

不仅如此，两个富人在给自己创造财富的同时，也给三个穷人增加了就业机会和劳动收入。

那样，在两个富人每人的财富总额达到1.2万元的时候，三个穷人每人的财富也就可能不再是2000元，而是3000元或者5000元。

法国有位贫穷的年轻人，经过十年的艰苦奋斗，终于成为媒体大亨，跻身于法国50名大富翁之列。

1998年他去世，将自己的遗嘱刊登在当地报纸上，说：我也曾是穷人，知道“穷人最缺少的是什么”的人，将得到100万法郎的奖赏。

几乎有两万人争先恐后地寄来了自己的答案。

答案五花八门。

大部分的人认为，穷人最缺少的是金钱。

另一部分人认为，穷人最缺少的是机会、技能……但没有人答对。

一年后，他的律师公开了答案：“穷人最缺少的，是成为富人的野心！”这个谜底震动了欧美，几乎所有的富人都予以认可，说出了自己成为富人的关键所在。

这里说的“野心”，准确地说，应该是我们常讲的“雄心壮志”。

我们难以设想，一个心志不高的人，一个没有远大目标的人，连一张蓝图都没有的人，能够创造出什么奇迹。

通常对富人之所以能致富，较负面的想法是认为他们运气好或从事不正当的行业；较正面的想法是认为他们更努力或克勤克俭。

但万万没想到，真正的原因在于他们的理财习惯不同。

投资致富的先决条件是将资产投资于高报酬率的投资标的上。

网络热词“土豪”的语‎言学解读网络热词“‎土豪”的语言学解读‎文章从语言学角度对‎土豪一词的新旧词义‎变化进行了解读。

‎【关键词】‎土豪；语言学；词义‎在201X年度十大‎热词榜上，土豪位‎列第二。

土豪这个‎原本已经走进历史的词‎语摇身一变重新进入交‎际领域，并且迅速蔓延‎到论文格式论文‎范文毕业论文‎【摘要】文章从语言‎学角度对“土豪”一‎词的新旧词义变化进行‎了解读。

【关键‎词】土豪‎；语言学；词义在‎201X年度十大热词‎榜上，“土豪”位列第‎二。

“土豪”这个原本‎已经走进历史的词语摇‎身一变重新进入交际领‎域，并且迅速蔓延到了‎舆论场之中。

作为一种‎语言现象，“土豪”一‎词的演变需要我们从语‎言学角度来认识和解读‎。

一、‎“土豪”的旧义土‎豪，《辞源》释义：‎地方上的豪强、‎恶霸；《现代汉语词典‎》释义：旧时‎农村中有钱有势的地主‎或恶霸。

“土豪”常与‎“劣绅”并用。

毛泽东‎《怎样分析农村阶级》‎指出：“军阀‎、官僚、土豪、劣绅是‎地主阶级的政治代表，‎是地主中特别凶恶者。

‎”土豪，从词性上来说‎是名词，通常用来指恶‎人，因此带贬义色彩。

‎“土豪”早期为人们所‎熟悉，是源于上世纪三‎十年代土地革命时期“‎打土豪，分田地”的标‎语。

在那种革命时代的‎语境下，“土豪”，是‎横行乡里的地主、恶霸‎，是被专政的对象，他‎们的身上贴有为富不仁‎、盘剥贫苦农民的标签‎。

随着地主土豪们被打‎倒而退出历史舞台，人‎民当家作主建立了新中‎国，“土豪”一词也就‎慢慢失去了交际价值，‎成为历史词，只保留在‎历史文献和反映历史的‎文学作品中。

‎二、“土豪”的‎新义一段时间以来‎，“土豪”突然成为一‎个极具传播性的网络新‎词，进而在主流报刊传‎媒上开始频繁出现。

‎随后，“土豪”便以‎不可阻挡之势，被媒体‎广泛应用于社会方方面‎面。

百度百科原有“土‎豪”一词在基本释义基‎础上，增加了网络释义‎，指网络上无脑消费的‎人，用来讽刺那些有钱‎又很喜欢炫耀的人，并‎于短时间内数十次更新‎释义内容；创建新词条‎“土豪金”，因苹果新‎一代手机登陆中国市场‎，其中金色版本成了最‎热销的一种颜色，并且‎售价不菲，成为土豪们‎的首选，所以把此颜色‎称之为“土豪金”，暗‎示该种金色为土豪区别‎身份之用途；创建新词‎条“土豪诗”，其基本‎形式是将语意相连的两‎句古典诗词名句的后一‎句改为含有“土豪”一‎词的句子，造成一种亦‎庄亦谐的效果，并迅速‎成为走红网络的新文体‎。

enfants riches deprime标识概述及解释说明1. 引言1.1 概述本文旨在探讨富裕儿童心理问题中的一种现象，即"enfants riches deprime"。

这个法语词汇的意思是"富裕儿童抑郁症"，指的是来自富裕家庭的孩子们所面临的心理困扰和压力。

随着经济社会的发展和生活水平的提高，越来越多的家庭可以给予孩子更好的物质条件和教育资源，但同时也带来了一系列问题。

由于物质充裕以及环境优越，人们往往认为这些孩子应该没有什么心理问题。

然而事实却并非如此。

1.2 文章结构本文将分为五个部分进行论述。

首先是引言部分，通过概述和文章结构来介绍本篇长文的内容框架。

紧接着，在第二部分中将对"enfants riches deprime"进行标识和解释。

第三部分将详细探讨富裕儿童所面临的心理问题，包括心理压力、自我认同困扰以及社交问题等方面。

在第四部分中，我们将从家庭环境和教育压力的影响、变革家庭价值观念和教育理念，以及提供心理支持与指导服务等角度，分析富裕儿童心理问题的原因并提出解决方案。

最后，在第五部分中，我们将总结讨论对富裕儿童心理问题的意义和影响，并展望未来的研究方向和建议措施。

1.3 目的本文旨在引起人们对富裕儿童心理问题的关注，在深入了解这一现象的基础上，探讨其对孩子们所造成的影响以及可能存在的解决方案。

通过这样的研究和探讨，我们希望为关注富裕儿童心理健康发展的家长、教育者以及社会各界提供参考，并为进一步研究提供思路和启示。

2. 标识和解释2.1 标识在现代社会中，我们常常听到一个词汇“enfants riches deprime”（富裕儿童的抑郁），它指的是来自富裕家庭的孩子们面临心理问题和困扰。

这个标识主要用来描述那些生活条件优越但却经历情感困扰的孩子们。

2.2 解释说明富裕儿童的抑郁是一个复杂而多维度的现象，其中包含许多不同因素的交织影响。

富集rich factor取值范围-概述说明以及解释1.引言1.1 概述富集rich factor是一种用来评估某个物质在特定环境中的丰度程度的数值指标。

在生物学、化学、环境科学等领域，富集rich factor都被广泛应用于研究中。

通过计算这一指标，可以帮助研究人员更好地了解物质在环境中的分布情况，从而进一步推断其可能对生态系统或人类健康造成的影响。

富集rich factor的计算方法基于物质在不同环境介质中的分布比例，通常通过测定样本中目标物质的含量和环境中总体物质的含量，并进行比较和计算得出。

富集rich factor的数值范围可以帮助确定物质的富集情况，从而指导相关研究或实践工作的进行。

本文将对富集rich factor的定义、计算方法以及应用范围进行详细介绍和分析，旨在帮助读者更好地理解和应用这一重要指标。

1.2 文章结构文章结构部分主要包括以下几个方面：1. 引言：介绍文章的背景和目的，引出富集rich factor的定义和计算方法。

2. 正文：详细阐述富集rich factor的定义、计算方法以及应用范围，包括对其在科研、生物学等领域的意义和价值。

3. 结论：总结文章的主要内容和结论，评价富集rich factor的重要性，并展望其未来的发展方向。

通过以上结构，读者可以清晰地了解整篇文章的内容和脉络，有助于更好地理解和掌握富集rich factor的相关知识。

1.3 目的富集rich factor是一种重要的指标，用于衡量某种物质在特定环境中的丰度水平。

本篇文章旨在探讨富集rich factor的取值范围，通过了解其定义、计算方法和应用范围，进一步了解该指标在环境学、生态学和地球化学等领域的意义和应用价值。

通过对富集rich factor的深入研究，可以帮助我们更好地理解物质在环境中的分布规律，为环境保护和资源利用提供科学依据。

同时，本文旨在为相关研究者提供参考和借鉴，促进该领域的进一步发展和探索。

HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationFLUOXETINE HClC17H18F3NO•HClM.W. = 345.79CAS — 59333-67-4STABILITY INDICATINGA S S A Y V A L I D A T I O NMethod is suitable for:ýIn-process controlþProduct ReleaseþStability indicating analysis (Suitability - US/EU Product) CAUTIONFLUOXETINE HYDROCHLORIDE IS A HAZARDOUS CHEMICAL AND SHOULD BE HANDLED ONLY UNDER CONDITIONS SUITABLE FOR HAZARDOUS WORK.IT IS HIGHLY PRESSURE SENSITIVE AND ADEQUATE PRECAUTIONS SHOULD BE TAKEN TO AVOID ANY MECHANICAL FORCE (SUCH AS GRINDING, CRUSHING, ETC.) ON THE POWDER.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationTABLE OF CONTENTS INTRODUCTION........................................................................................................................ PRECISION............................................................................................................................... System Repeatability ................................................................................................................ Method Repeatability................................................................................................................. Intermediate Precision .............................................................................................................. LINEARITY................................................................................................................................ RANGE...................................................................................................................................... ACCURACY............................................................................................................................... Accuracy of Standard Injections................................................................................................ Accuracy of the Drug Product.................................................................................................... VALIDATION OF FLUOXETINE HCl AT LOW CONCENTRATION........................................... Linearity at Low Concentrations................................................................................................. Accuracy of Fluoxetine HCl at Low Concentration..................................................................... System Repeatability................................................................................................................. Quantitation Limit....................................................................................................................... Detection Limit........................................................................................................................... VALIDATION FOR META-FLUOXETINE HCl (POSSIBLE IMPURITIES).................................. Meta-Fluoxetine HCl linearity at 0.05% - 1.0%........................................................................... Detection Limit for Fluoxetine HCl.............................................................................................. Quantitation Limit for Meta Fluoxetine HCl................................................................................ Accuracy for Meta-Fluoxetine HCl ............................................................................................ Method Repeatability for Meta-Fluoxetine HCl........................................................................... Intermediate Precision for Meta-Fluoxetine HCl......................................................................... SPECIFICITY - STABILITY INDICATING EVALUATION OF THE METHOD............................. FORCED DEGRADATION OF FINISHED PRODUCT AND STANDARD..................................1. Unstressed analysis...............................................................................................................2. Acid Hydrolysis stressed analysis..........................................................................................3. Base hydrolysis stressed analysis.........................................................................................4. Oxidation stressed analysis...................................................................................................5. Sunlight stressed analysis.....................................................................................................6. Heat of solution stressed analysis.........................................................................................7. Heat of powder stressed analysis.......................................................................................... System Suitability stressed analysis.......................................................................................... Placebo...................................................................................................................................... STABILITY OF STANDARD AND SAMPLE SOLUTIONS......................................................... Standard Solution...................................................................................................................... Sample Solutions....................................................................................................................... ROBUSTNESS.......................................................................................................................... Extraction................................................................................................................................... Factorial Design......................................................................................................................... CONCLUSION...........................................................................................................................ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationBACKGROUNDTherapeutically, Fluoxetine hydrochloride is a classified as a selective serotonin-reuptake inhibitor. Effectively used for the treatment of various depressions. Fluoxetine hydrochloride has been shown to have comparable efficacy to tricyclic antidepressants but with fewer anticholinergic side effects. The patent expiry becomes effective in 2001 (US). INTRODUCTIONFluoxetine capsules were prepared in two dosage strengths: 10mg and 20mg dosage strengths with the same capsule weight. The formulas are essentially similar and geometrically equivalent with the same ingredients and proportions. Minor changes in non-active proportions account for the change in active ingredient amounts from the 10 and 20 mg strength.The following validation, for the method SI-IAG-206-02 , includes assay and determination of Meta-Fluoxetine by HPLC, is based on the analytical method validation SI-IAG-209-06. Currently the method is the in-house method performed for Stability Studies. The Validation was performed on the 20mg dosage samples, IAG-21-001 and IAG-21-002.In the forced degradation studies, the two placebo samples were also used. PRECISIONSYSTEM REPEATABILITYFive replicate injections of the standard solution at the concentration of 0.4242mg/mL as described in method SI-IAG-206-02 were made and the relative standard deviation (RSD) of the peak areas was calculated.SAMPLE PEAK AREA#15390#25406#35405#45405#55406Average5402.7SD 6.1% RSD0.1ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::PRECISION - Method RepeatabilityThe full HPLC method as described in SI-IAG-206-02 was carried-out on the finished product IAG-21-001 for the 20mg dosage form. The method repeated six times and the relative standard deviation (RSD) was calculated.SAMPLENumber%ASSAYof labeled amountI 96.9II 97.8III 98.2IV 97.4V 97.7VI 98.5(%) Average97.7SD 0.6(%) RSD0.6PRECISION - Intermediate PrecisionThe full method as described in SI-IAG-206-02 was carried-out on the finished product IAG-21-001 for the 20mg dosage form. The method was repeated six times by a second analyst on a different day using a different HPLC instrument. The average assay and the relative standard deviation (RSD) were calculated.SAMPLENumber% ASSAYof labeled amountI 98.3II 96.3III 94.6IV 96.3V 97.8VI 93.3Average (%)96.1SD 2.0RSD (%)2.1The difference between the average results of method repeatability and the intermediate precision is 1.7%.HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationLINEARITYStandard solutions were prepared at 50% to 200% of the nominal concentration required by the assay procedure. Linear regression analysis demonstrated acceptability of the method for quantitative analysis over the concentration range required. Y-Intercept was found to be insignificant.RANGEDifferent concentrations of the sample (IAG-21-001) for the 20mg dosage form were prepared, covering between 50% - 200% of the nominal weight of the sample.Conc. (%)Conc. (mg/mL)Peak Area% Assayof labeled amount500.20116235096.7700.27935334099.21000.39734463296.61500.64480757797.52000.79448939497.9(%) Average97.6SD 1.0(%) RSD 1.0ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::RANGE (cont.)The results demonstrate linearity as well over the specified range.Correlation coefficient (RSQ)0.99981 Slope11808.3Y -Interceptresponse at 100%* 100 (%) 0.3%ACCURACYACCURACY OF STANDARD INJECTIONSFive (5) replicate injections of the working standard solution at concentration of 0.4242mg/mL, as described in method SI-IAG-206-02 were made.INJECTIONNO.PEAK AREA%ACCURACYI 539299.7II 540599.9III 540499.9IV 5406100.0V 5407100.0Average 5402.899.9%SD 6.10.1RSD, (%)0.10.1The percent deviation from the true value wasdetermined from the linear regression lineHPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::ACCURACY OF THE DRUG PRODUCTAdmixtures of non-actives (placebo, batch IAG-21-001 ) with Fluoxetine HCl were prepared at the same proportion as in a capsule (70%-180% of the nominal concentration).Three preparations were made for each concentration and the recovery was calculated.Conc.(%)Placebo Wt.(mg)Fluoxetine HCl Wt.(mg)Peak Area%Accuracy Average (%)70%7079.477.843465102.27079.687.873427100.77079.618.013465100.0101.0100%10079.6211.25476397.910080.8011.42491799.610079.6011.42485498.398.6130%13079.7214.90640599.413080.3114.75632899.213081.3314.766402100.399.618079.9920.10863699.318079.3820.45879499.418080.0820.32874899.599.4Placebo, Batch Lot IAG-21-001HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::VALIDATION OF FLUOXETINE HClAT LOW CONCENTRATIONLINEARITY AT LOW CONCENTRATIONSStandard solution of Fluoxetine were prepared at approximately 0.02%-1.0% of the working concentration required by the method SI-IAG-206-02. Linear regression analysis demonstrated acceptability of the method for quantitative analysis over this range.ACCURACY OF FLUOXETINE HCl AT LOW CONCENTRATIONThe peak areas of the standard solution at the working concentration were measured and the percent deviation from the true value, as determined from the linear regression was calculated.SAMPLECONC.µg/100mLAREA FOUND%ACCURACYI 470.56258499.7II 470.56359098.1III 470.561585101.3IV 470.561940100.7V 470.56252599.8VI 470.56271599.5(%) AverageSlope = 132.7395299.9SD Y-Intercept = -65.872371.1(%) RSD1.1HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSystem RepeatabilitySix replicate injections of standard solution at 0.02% and 0.05% of working concentration as described in method SI-IAG-206-02 were made and the relative standard deviation was calculated.SAMPLE FLUOXETINE HCl AREA0.02%0.05%I10173623II11503731III10103475IV10623390V10393315VI10953235Average10623462RSD, (%) 5.0 5.4Quantitation Limit - QLThe quantitation limit ( QL) was established by determining the minimum level at which the analyte was quantified. The quantitation limit for Fluoxetine HCl is 0.02% of the working standard concentration with resulting RSD (for six injections) of 5.0%. Detection Limit - DLThe detection limit (DL) was established by determining the minimum level at which the analyte was reliably detected. The detection limit of Fluoxetine HCl is about 0.01% of the working standard concentration.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::VALIDATION FOR META-FLUOXETINE HCl(EVALUATING POSSIBLE IMPURITIES)Meta-Fluoxetine HCl linearity at 0.05% - 1.0%Relative Response Factor (F)Relative response factor for Meta-Fluoxetine HCl was determined as slope of Fluoxetine HCl divided by the slope of Meta-Fluoxetine HCl from the linearity graphs (analysed at the same time).F =132.7395274.859534= 1.8Detection Limit (DL) for Fluoxetine HClThe detection limit (DL) was established by determining the minimum level at which the analyte was reliably detected.Detection limit for Meta Fluoxetine HCl is about 0.02%.Quantitation Limit (QL) for Meta-Fluoxetine HClThe QL is determined by the analysis of samples with known concentration of Meta-Fluoxetine HCl and by establishing the minimum level at which the Meta-Fluoxetine HCl can be quantified with acceptable accuracy and precision.Six individual preparations of standard and placebo spiked with Meta-Fluoxetine HCl solution to give solution with 0.05% of Meta Fluoxetine HCl, were injected into the HPLC and the recovery was calculated.HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::META-FLUOXETINE HCl[RECOVERY IN SPIKED SAMPLES].Approx.Conc.(%)Known Conc.(µg/100ml)Area in SpikedSampleFound Conc.(µg/100mL)Recovery (%)0.0521.783326125.735118.10.0521.783326825.821118.50.0521.783292021.55799.00.0521.783324125.490117.00.0521.783287220.96996.30.0521.783328526.030119.5(%) AVERAGE111.4SD The recovery result of 6 samples is between 80%-120%.10.7(%) RSDQL for Meta Fluoxetine HCl is 0.05%.9.6Accuracy for Meta Fluoxetine HClDetermination of Accuracy for Meta-Fluoxetine HCl impurity was assessed using triplicate samples (of the drug product) spiked with known quantities of Meta Fluoxetine HCl impurity at three concentrations levels (namely 80%, 100% and 120% of the specified limit - 0.05%).The results are within specifications:For 0.4% and 0.5% recovery of 85% -115%For 0.6% recovery of 90%-110%HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::META-FLUOXETINE HCl[RECOVERY IN SPIKED SAMPLES]Approx.Conc.(%)Known Conc.(µg/100mL)Area in spikedSample Found Conc.(µg/100mL)Recovery (%)[0.4%]0.4174.2614283182.66104.820.4174.2614606187.11107.370.4174.2614351183.59105.36[0.5%]0.5217.8317344224.85103.220.5217.8316713216.1599.230.5217.8317341224.81103.20[0.6%]0.6261.3918367238.9591.420.6261.3920606269.81103.220.6261.3920237264.73101.28RECOVERY DATA DETERMINED IN SPIKED SAMPLESHPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::REPEATABILITYMethod Repeatability - Meta Fluoxetine HClThe full method (as described in SI-IAG-206-02) was carried out on the finished drug product representing lot number IAG-21-001-(1). The HPLC method repeated serially, six times and the relative standard deviation (RSD) was calculated.IAG-21-001 20mg CAPSULES - FLUOXETINESample% Meta Fluoxetine % Meta-Fluoxetine 1 in Spiked Solution10.0260.09520.0270.08630.0320.07740.0300.07450.0240.09060.0280.063AVERAGE (%)0.0280.081SD 0.0030.012RSD, (%)10.314.51NOTE :All results are less than QL (0.05%) therefore spiked samples with 0.05% Meta Fluoxetine HCl were injected.HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::Intermediate Precision - Meta-Fluoxetine HClThe full method as described in SI-IAG-206-02 was applied on the finished product IAG-21-001-(1) .It was repeated six times, with a different analyst on a different day using a different HPLC instrument.The difference between the average results obtained by the method repeatability and the intermediate precision was less than 30.0%, (11.4% for Meta-Fluoxetine HCl as is and 28.5% for spiked solution).IAG-21-001 20mg - CAPSULES FLUOXETINESample N o:Percentage Meta-fluoxetine% Meta-fluoxetine 1 in spiked solution10.0260.06920.0270.05730.0120.06140.0210.05850.0360.05560.0270.079(%) AVERAGE0.0250.063SD 0.0080.009(%) RSD31.514.51NOTE:All results obtained were well below the QL (0.05%) thus spiked samples slightly greater than 0.05% Meta-Fluoxetine HCl were injected. The RSD at the QL of the spiked solution was 14.5%HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSPECIFICITY - STABILITY INDICATING EVALUATIONDemonstration of the Stability Indicating parameters of the HPLC assay method [SI-IAG-206-02] for Fluoxetine 10 & 20mg capsules, a suitable photo-diode array detector was incorporated utilizing a commercial chromatography software managing system2, and applied to analyze a range of stressed samples of the finished drug product.GLOSSARY of PEAK PURITY RESULT NOTATION (as reported2):Purity Angle-is a measure of spectral non-homogeneity across a peak, i.e. the weighed average of all spectral contrast angles calculated by comparing all spectra in the integrated peak against the peak apex spectrum.Purity Threshold-is the sum of noise angle3 and solvent angle4. It is the limit of detection of shape differences between two spectra.Match Angle-is a comparison of the spectrum at the peak apex against a library spectrum.Match Threshold-is the sum of the match noise angle3 and match solvent angle4.3Noise Angle-is a measure of spectral non-homogeneity caused by system noise.4Solvent Angle-is a measure of spectral non-homogeneity caused by solvent composition.OVERVIEWT he assay of the main peak in each stressed solution is calculated according to the assay method SI-IAG-206-02, against the Standard Solution, injected on the same day.I f the Purity Angle is smaller than the Purity Threshold and the Match Angle is smaller than the Match Threshold, no significant differences between spectra can be detected. As a result no spectroscopic evidence for co-elution is evident and the peak is considered to be pure.T he stressed condition study indicated that the Fluoxetine peak is free from any appreciable degradation interference under the stressed conditions tested. Observed degradation products peaks were well separated from the main peak.1® PDA-996 Waters™ ; 2[Millennium 2010]ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationFORCED DEGRADATION OF FINISHED PRODUCT & STANDARD 1.UNSTRESSED SAMPLE1.1.Sample IAG-21-001 (2) (20mg/capsule) was prepared as stated in SI-IAG-206-02 and injected into the HPLC system. The calculated assay is 98.5%.SAMPLE - UNSTRESSEDFluoxetine:Purity Angle:0.075Match Angle:0.407Purity Threshold:0.142Match Threshold:0.4251.2.Standard solution was prepared as stated in method SI-IAG-206-02 and injected into the HPLC system. The calculated assay is 100.0%.Fluoxetine:Purity Angle:0.078Match Angle:0.379Purity Threshold:0.146Match Threshold:0.4272.ACID HYDROLYSIS2.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as in method SI-IAG-206-02 : An amount equivalent to 20mg Fluoxetine was weighed into a 50mL volumetric flask. 20mL Diluent was added and the solution sonicated for 10 minutes. 1mL of conc. HCl was added to this solution The solution was allowed to stand for 18 hours, then adjusted to about pH = 5.5 with NaOH 10N, made up to volume with Diluent and injected into the HPLC system after filtration.Fluoxetine peak intensity did NOT decrease. Assay result obtained - 98.8%.SAMPLE- ACID HYDROLYSISFluoxetine peak:Purity Angle:0.055Match Angle:0.143Purity Threshold:0.096Match Threshold:0.3712.2.Standard solution was prepared as in method SI-IAG-206-02 : about 22mg Fluoxetine HCl were weighed into a 50mL volumetric flask. 20mL Diluent were added. 2mL of conc. HCl were added to this solution. The solution was allowed to stand for 18 hours, then adjusted to about pH = 5.5 with NaOH 10N, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity did NOT decrease. Assay result obtained - 97.2%.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSTANDARD - ACID HYDROLYSISFluoxetine peak:Purity Angle:0.060Match Angle:0.060Purity Threshold:0.099Match Threshold:0.3713.BASE HYDROLYSIS3.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as per method SI-IAG-206-02 : An amount equivalent to 20mg Fluoxetine was weight into a 50mL volumetric flask. 20mL Diluent was added and the solution sonicated for 10 minutes. 1mL of 5N NaOH was added to this solution. The solution was allowed to stand for 18 hours, then adjusted to about pH = 5.5 with 5N HCl, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity did NOT decrease. Assay result obtained - 99.3%.SAMPLE - BASE HYDROLYSISFluoxetine peak:Purity Angle:0.063Match Angle:0.065Purity Threshold:0.099Match Threshold:0.3623.2.Standard stock solution was prepared as per method SI-IAG-206-02 : About 22mg Fluoxetine HCl was weighed into a 50mL volumetric flask. 20mL Diluent was added. 2mL of 5N NaOH was added to this solution. The solution was allowed to stand for 18 hours, then adjusted to about pH=5.5 with 5N HCl, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity did NOT decrease - 99.5%.STANDARD - BASE HYDROLYSISFluoxetine peak:Purity Angle:0.081Match Angle:0.096Purity Threshold:0.103Match Threshold:0.3634.OXIDATION4.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as per method SI-IAG-206-02. An equivalent to 20mg Fluoxetine was weighed into a 50mL volumetric flask. 20mL Diluent added and the solution sonicated for 10 minutes.1.0mL of 30% H2O2 was added to the solution and allowed to stand for 5 hours, then made up to volume with Diluent, filtered and injected into HPLC system.Fluoxetine peak intensity decreased to 95.2%.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSAMPLE - OXIDATIONFluoxetine peak:Purity Angle:0.090Match Angle:0.400Purity Threshold:0.154Match Threshold:0.4294.2.Standard solution was prepared as in method SI-IAG-206-02 : about 22mg Fluoxetine HCl were weighed into a 50mL volumetric flask and 25mL Diluent were added. 2mL of 30% H2O2 were added to this solution which was standing for 5 hours, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity decreased to 95.8%.STANDARD - OXIDATIONFluoxetine peak:Purity Angle:0.083Match Angle:0.416Purity Threshold:0.153Match Threshold:0.4295.SUNLIGHT5.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as in method SI-IAG-206-02 . The solution was exposed to 500w/hr. cell sunlight for 1hour. The BST was set to 35°C and the ACT was 45°C. The vials were placed in a horizontal position (4mm vials, National + Septum were used). A Dark control solution was tested. A 2%w/v quinine solution was used as the reference absorbance solution.Fluoxetine peak decreased to 91.2% and the dark control solution showed assay of 97.0%. The difference in the absorbance in the quinine solution is 0.4227AU.Additional peak was observed at RRT of 1.5 (2.7%).The total percent of Fluoxetine peak with the degradation peak is about 93.9%.SAMPLE - SUNLIGHTFluoxetine peak:Purity Angle:0.093Match Angle:0.583Purity Threshold:0.148Match Threshold:0.825 ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSUNLIGHT (Cont.)5.2.Working standard solution was prepared as in method SI-IAG-206-02 . The solution was exposed to 500w/hr. cell sunlight for 1.5 hour. The BST was set to 35°C and the ACT was 42°C. The vials were placed in a horizontal position (4mm vials, National + Septum were used). A Dark control solution was tested. A 2%w/v quinine solution was used as the reference absorbance solution.Fluoxetine peak was decreased to 95.2% and the dark control solution showed assay of 99.5%.The difference in the absorbance in the quinine solution is 0.4227AU.Additional peak were observed at RRT of 1.5 (2.3).The total percent of Fluoxetine peak with the degradation peak is about 97.5%. STANDARD - SUNLIGHTFluoxetine peak:Purity Angle:0.067Match Angle:0.389Purity Threshold:0.134Match Threshold:0.8196.HEAT OF SOLUTION6.1.Sample solution of IAG-21-001-(2) (20 mg/capsule) was prepared as in method SI-IAG-206-02 . Equivalent to 20mg Fluoxetine was weighed into a 50mL volumetric flask. 20mL Diluent was added and the solution was sonicated for 10 minutes and made up to volume with Diluent. 4mL solution was transferred into a suitable crucible, heated at 105°C in an oven for 2 hours. The sample was cooled to ambient temperature, filtered and injected into the HPLC system.Fluoxetine peak was decreased to 93.3%.SAMPLE - HEAT OF SOLUTION [105o C]Fluoxetine peak:Purity Angle:0.062Match Angle:0.460Purity Threshold:0.131Match Threshold:0.8186.2.Standard Working Solution (WS) was prepared under method SI-IAG-206-02 . 4mL of the working solution was transferred into a suitable crucible, placed in an oven at 105°C for 2 hours, cooled to ambient temperature and injected into the HPLC system.Fluoxetine peak intensity did not decrease - 100.5%.ED. N0: 04Effective Date:APPROVED::。

rich的用法总结大全rich有富有的,肥沃的,丰富多彩的,油腻的的意思。

那你们想知道rich的用法吗?今天给大家带来了rich的用法,希望能够帮助到大家，一起来学习吧。

rich的用法总结大全rich的意思adj. 富有的,肥沃的,丰富多彩的,油腻的变形：比较级：richer; 最高级：richest;rich用法rich可以用作形容词rich的基本意思是“富的,富裕的,富有的”,可指某人很有钱,也可指某物看上去很奢华,给人一种名贵的感觉,即“贵重的,昂贵的,华丽的”,或指某物的储藏量大,即“盛产,丰富,多”。

rich引申可指“丰产的,肥沃的”“油腻的,味浓的”“深的,鲜艳的,深沉的,洪亮的”等。

在口语中rich还可指“有趣的,荒唐的”。

rich在句中可用作定语,也可用作表语。

用作表语时,其后常接由介词in引导的短语,意为“盛产…的”“含有大量…的”。

the rich可用来表示“富人”,谓语动词要用复数,在口语中,定冠词the常可省略,而且rich前可加形容词。

rich用作形容词的用法例句He is a rich man.他是一个富有的人。

The rich man left his son nothing in the will.那位富翁在遗嘱中什么都没给他儿子留下。

Our country is a rich land.我们是一个富饶的国家。

rich用法例句1、He hoped to strike it rich by investing in ginseng.他希望通过投资人参发大财。

2、We gained a rich supply of data which would normally be inaccessible.我们得到了通常难以获取的大量数据。

3、Liver and kidney are particularly rich in vitamin A.肝脏和肾脏富含维生素A。

Thats rich可不是在夸你很有钱!!!rich大家都知道是指很有钱，表示“富有的”，“富裕的”。

富豪的四大致富基因来源：中国营销传播网作者：梁胜威成为富人，这是许多人都有的共同愿望，为了达成这一目标，人们不惜一切代价、不怕铤而走险，于是，很多人都在寻找发财途径，寻找发财秘诀。

我不知道秘诀是否存在，但我经过考察了很多成功老板之后，发现在他们身上还是有成功因素存在的。

我把这种成功因素称之为“致富基因”。

因此，你要想成为老板，首先看看自己有没有这种“致富基因”。

当然，这种基因不是遗传基因，而是在你的头脑里养成的一些思维习惯和行为习惯。

那么，富人有哪些“致富基因”？第一、强烈的致富欲望强烈的致富欲望是成功的先决条件。

从深层次来讲每个人都有成为富人的渴望，但又似乎觉得这离自己太远了，他们都会不知不觉地有这样的想法：“成为富翁，我可能吗？”于是也就大都安于目前的现状，没有去考虑改变自己的生存状态。

但在现实生活中发生的故事却往往截然相反，它恰恰印证了这样一句话：没有做不到的，只有想不到的。

我以前看过一本书，说一个富豪他在介绍致富经历时说，他还在读中学时，有一天他母亲问他：“你知道我们为什么贫穷吗？”年轻的他摇摇头。

母亲接着说：“孩子，那是因为你爸爸从来就没有想过要做富人，他一天到晚从船上回来倒头就睡。

儿子，你如果要想致富，首先你得努力去想怎么样才能致富，如何致富。

”从这次谈话开始，富豪的脑袋里整天装着都是如何致富的问题，然后努力寻找致富机会。

终于皇天不负有心人，机会来了，他把那些烂渔船低价收回来，卖给一家做船木家私的厂家。

这样一来二去，他在学生年代就这样赚了第一桶金。

整天想着发财不是贪婪，而是一种勇气，一种渴望成功的冲动，是一种野心。

而另一种后来成为富豪的人则是因为从小家贫，贫穷和饥饿促使他们“穷人的孩子早当家”，家庭生活的重压也使他对金钱有了更深的理解，从而养成了一种不放过任何发财机会的习惯，这就是日后培养成了他们的致富基因。

所以，发财的野心几乎成为所有后来成富豪的最原始的基因。

第二、投资思维的习惯有人说过，要想成为富人，首先要学会像富人那样思考问题。

rich的中文翻译
rich的中文翻译是“富有”。

rick 是一个形容词，指财富丰富、拥有大量财产和金钱的人或物。

例如，你可以说“Jack is a very rich man”（杰克是一个非常富有的人）。

而rick这个字也可以用在更广泛的情况下，比如一个国家“The country is rich in natural resources”（这个国家资源丰富）。

在古希腊神话中，有一个人物叫做Rick，他是财富的神灵。

他拥有比其他人更多的财富，可以帮助人们实现财富梦想。

除了古希腊，在其他文化中，RICH也指代着财富、财富、力量和辉煌，是无尽的财富和荣耀的象征。

在现代英语中，rick也用于描述一种某种特性非常丰富的情形，比如“Richard is a very culturally rich person”（Richard是一个文化上非常丰富的人）。

因此，rick不仅指代金钱的财富，它还可以用来描述一种特定的丰富的特性。